Immunotherapy Guide Increases Dosing Accuracy. Jared Darveaux, MD

Similar documents
Venom Hypersensitivity

e. Elm Correct Question 2 Which preservative/adjuvant has the greatest potential to breakdown immunotherapy because of protease activity? a.

Completing the NPA online Patient Safety Incident Report form: 2016

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION

2017 Optum, Inc. All rights reserved BH1124_112017

New Frontiers in Allergen Immunotherapy

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Annual Assembly Abstract Review Process

Related Policies None

Medication Assisted Treatment for Opioid Use Disorder in Rural Colorado

ImmunoCAP. Specific IgE blood test

ALCAT FREQUENTLY ASKED QUESTIONS

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?

Programme of Learning. Physical Education. Key Stage 4 Year 10 BTEC Sport

Osteoporosis Fast Facts

Methadone Maintenance Treatment for Opioid Dependence

Public consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking

Safety of HPV vaccination: A FIGO STATEMENT

Pain Management Learning Plan

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by

SECTION O. MEDICATIONS

Cardiac Rehabilitation Services

US Public Health Service Clinical Practice Guidelines for PrEP

Original Policy Date 12:2013

Health Consumers Queensland submission

1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT

The principles of evidence-based medicine

TOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

CLINICAL MEDICAL POLICY

Implementation of G6PD testing and radical cure in P. vivax endemic countries: considerations

HPV VACCINATION IN SANDYFORD SERVICES

Pennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain

A. Catalonia World Health Organization Demonstration Project

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

Monensin and Extruded Urea-Grain for Range Beef Cows

Commissioning Policy: South Warwickshire CCG (SWCCG)

Pediatric and adolescent preventive care and HEDIS *

RoActemra (tocilizumab) for Giant Cell Arteritis (GCA) subcutaneous (SC) formulation

PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS

MEDICATION GUIDE. (Interferon alfa-2b)

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

Rate Lock Policy. Contents

Table of Contents (Click on title to jump to section)

EAGLE CARE A SPORT CLUB CONCUSSION MANAGEMENT MODEL

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH

2018 Medical Association Poster Symposium Guidelines

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.

Neurological outcome from conservative or surgical treatment of cervical spinal cord injured patients

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan

PET FORM Planning and Evaluation Tracking ( Assessment Period)

Thank you for committing to engage pharmacists regarding the incredible opportunity for them to prevent opioid overdose deaths by providing naloxone!

VITAPRO. Detoxification properties of Apple pectin formulation, PROPECTIN. CENTRE D ETUDE ET DE VALORISATION DES ALGUES FINAL REPORT.

Swindon Joint Strategic Needs Assessment Bulletin

Use of SLIT in allergy practice: Is it ready for prime time? Stanley Fineman, MD, MBA Atlanta Allergy & Asthma Clinic AAIFNC, Feb 7, 2015

EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE

PATIENT INFORMATION. effective for the treatment of the flu in people with long-time (chronic) heart problems or breathing problems.

Corporate Governance Code for Funds: What Will it Mean?

Dementia Cal MediConnect Project DEMENTIA CARE MANAGER TRAINING FACILITATOR GUIDE

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

Frequently Asked Questions: IS RT-Q-PCR Testing

Package leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate

A foot x-ray series is required only if there is pain in the midfoot zone and any one of the following:

Pain relief after surgery

PROTOCOL 1850 Millrace Drive, Suite 3A Eugene, Oregon

Improving Surveillance and Monitoring of Self-harm in Irish Prisons

NIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO

Lyme Disease Surveillance in North Carolina

A fake medicine that passes itself off as a real, authorised medicine. (1)

77 WHO/IPA workshop on Immunisation

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745

CDC Influenza Division Key Points MMWR Updates February 20, 2014

2018 CMS Web Interface

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers

CDC Influenza Division Key Points December 9, 2016

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

Appendix 1 Example of Homely Remedy Policy

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers

Recommendations for Surgery

Podcast Transcript Title: Common Miscoding of LARC Services Impacting Revenue Speaker Name: Ann Finn Duration: 00:16:10

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)

EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS

Evaluation of a Shared Decision Making Intervention between Patients and Providers to Improve Menopause Health Outcomes: Issue Brief

Widening of funding restrictions for rituximab and eltrombopag

Triumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media

FDA Dietary Supplement cgmp

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS

Protocol. Preparation Protocol for the Non-Targeted Vevo MicroMarker Contrast Agent

Tick fever is a cattle disease caused by any one of the following blood parasites:

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals.

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

Dental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care.

Policy. Medical Policy Manual Approved: Do Not Implement Until 1/1/18. Applied Behavioral Analysis (ABA)

CADTH Canadian Drug Expert Committee Recommendation

Recommendations for Risk Management at Swine Exhibitions and for Show Pigs August 2012

Transcription:

Immuntherapy Guide Increases Dsing Accuracy Jared Darveaux, MD

Disclsures Nne ON TARGET

Backgrund Immuntherapy (IT) is a therapeutic tl used t treat allergic rhinitis and allergic asthma fr decades In 2011, practice parameters were published n the practice f IT Within these practice parameters are recmmendatins n IT dses fr standardized and nn-standardized antigens These recmmendatins are meant t ptimize therapeutic results while minimizing the risk f adverse sht reactins

Backgrund In general, administratin f higher dses increases the likelihd f clinical effectiveness Lw dses are less likely t be effective, and very lw dses usually are ineffective

Recmmended Dses Multiple studies demnstrate that the efficacius dse fr allergen immuntherapy is between 5-20 μg f the majr allergen per injectin Based n clinical trials invlving single antigens Using recmmended dses is shwn t: Prvide early imprvement in symptms Alng with the duratin f treatment, imprves lngterm benefit

QI Prject Backgrund Many f the physicians in ur clinic utilized a chart created t simplify the IT rdering prcess Cncentratins f each antigen were based n the number f different antigens included in each vial While this chart was useful, it was created several years befre the recent practice parameters were released As such, utilizatin f this chart had the ptential t under r verdse IT prescriptins

Prject Aims T align the prcess f rdering IT with current practice parameter guidelines Simplify the IT rdering prcess Determine the effect f prviding a new dsing guide that adheres t practice parameters n dsing accuracy

Measures Review f the last 10 new IT rders (excluding venm) 55 allergen data pints Determined if prescribed dse fit within practice parameter guidelines Prescriptins were categrized as Very high: 2x the highest recmmended dse High: > recmmended maximum dse, < 2x recmmended maximum dse Apprpriate: within recmmended dse range Lw: < recmmended minimum dse, > 1/2 recmmended minimum dse Very Lw: 1/2 recmmended minimum dse N/A: nt applicable, n recmmendatins n dse

Lw 9% Dsing Accuracy All Antigens Apprpriate 25% Very lw 35% High 13% Very high 9% N/A 9% N = 55 antigen prescriptins

Lw 10% All Antigens (excluding mlds) Apprpriate 28% High 14% Very lw 38% Very high 10% N = 50 antigen prescriptins

Dsing Accuracy Standardized Antigens Apprpriate 46% Very lw 8% Very high 21% High 25% N = 24 antigen prescriptins Standardized extracts include cat, dust mite, grass, and ragweed

40 35 Accuracy by Schedule 30 % Accurate Dse 25 20 15 10 *Animal schedule 0% accurate 5 0 0.25 ML/SHOT 0.5 ML/SHOT 1 ML/SHOT ANIMAL (0.2 ML/SHOT)

Measures Cmmn Themes Prescriptins that were High and Very High were exclusively Grass and Ragweed Very few f the trees were dsed within the recmmended range Under-dsed All prescriptins in the "very lw" grup were either n a 0.25 ml/sht schedule r received a mix r bth All f the Rx written fr mixes (6 tree r cmmn weed) were very lw fr the individual antigens cntained in the mix

Mixes The maintenance cncentrate shuld be frmulated t deliver a dse cnsidered t be therapeutically effective fr each f its cnstituent cmpnents Eastern 6 tree mix recmmendatins fr pllens are within the range f 1:200 w/v 1:100 w/v Stck cncentratin = 20,000 PNU/ml = 1:46 w/v Cncentratin fr each f these unrelated allergens is nly 1/6 f this = 3,333 PNU/ml = 1:276 w/v Therefre, even at ur stck cncentratin n a 0.5 ml/sht schedule, a patient wuld receive 1,667 PNU per injectin = 1:552 w/v/antigen = majr underdse!

Interventin/Methds Created a new chart t be used as a guide fr IT dsing based ff f practice parameter recmmendatins New chart uses a 0.5 ml/sht schedule nly Mst IT Rx can achieve therapeutic dse with a 0.5 ml injectin 0.25 ml/injectin difficult t prvide sufficient dse in injectin amunt fr mst antigens

Antigen Target Dse Starting Cnc. Prescriptin Dse Apprx. Vl. (ml/10 ml vial) Lw Medium High Lw Medium High Ragweed Mix 6 12 AgE U 1:20 w/v 1:200 w/v 1:160 w/v 1:100 w/v 1 1.25 2 Pllen 1:200 1:100 w/v Cmmn Weed Mix a 20,000 PNU/ml 15,500 PNU/ml 20,000 PNU/ml 20,000 PNU/ml 7.75 10 10 Eastern 6 Tree Mix b 20,000 PNU/ml 20,000 PNU/ml 20,000 PNU/ml 20,000 PNU/ml 10 10 10 Eastern Oak Mix 20,000 PNU/ml 4,000 PNU/ml 5,000 PNU/ml 6,666 PNU/ml 2 2.5 3.33 Elm Mix 1:20 w/v 1:200 w/v 1:160 w/v 1:100 w/v 1 1.25 2 Birch Mix 20,000 PNU/ml 3,333 PNU/ml 5,000 PNU/ml 6,000 PNU/ml 1.66 2.5 3 Western Walnut Mix 20,000 PNU/ml 3,333 PNU/ml 5,000 PNU/ml 6,000 PNU/ml 1.66 2.5 3 Ash Mix 1:20 w/v 1:200 w/v 1:160 w/v 1:100 w/v 1 1.25 2 Maple/Bx Elder Mix 1:20 w/v 1:200 w/v 1:160 w/v 1:100 w/v 1 1.25 2 Hickry Mix 20,000 PNU/ml 4,000 PNU/ml 5,000 PNU/ml 6,666 PNU/ml 2 2.5 3.33 Willw/Black Salix Nigra 1:20 w/v 1:200 w/v 1:160 w/v 1:100 w/v 1 1.25 2 7 grass mix c 1,000 4,000 BAU 100,000 BAU/mL 2,000 BAU/ml 5,000 BAU/ml 8,000 BAU/ml 0.2 0.5 0.8 KORT 300 1500 BAU 10,000 BAU/ml 750 BAU/ml 1,500 BAU/ml 3,000 BAU/ml 0.75 1.5 3 Dust mite mix, Dp, r Df 500 2,000 AU 10,000 AU/ml 1,000 AU/ml 2,500 AU/ml 4,000 AU/ml 1 2.5 4 Cat hair/cat pelt 1,000 4,000 BAU 10,000 BAU/ml 2,000 BAU/ml 5,000 BAU/ml 8,000 BAU/ml 2 5 8 Dg 15 μg Can f 1 1:100 w/v 1:250 w/v 1:250 w/v 1:250 w/v 4 4 4 Fungi Highest Tlerated Alternaria Tenuis 20,000 PNU/ml 2,500 PNU/mL 5,000 PNU/ml 10,000 PNU/ml 1.25 2.5 5 Cladsprium Herbarum 20,000 PNU/ml 2,500 PNU/mL 5,000 PNU/ml 10,000 PNU/ml 1.25 2.5 5 Penicillium Mix 20,000 PNU/ml 2,500 PNU/mL 5,000 PNU/ml 10,000 PNU/ml 1.25 2.5 5 Aspergillus Fumigatus 20,000 PNU/ml 2,500 PNU/mL 5,000 PNU/ml 10,000 PNU/ml 1.25 2.5 5 Hrmdendrum Hrdei 1:20 w/v 1:160 w/v 1:80 w/v 1:40 w/v 1.25 2.5 5 Biplaris 20,000 PNU/ml 2,500 PNU/mL 5,000 PNU/ml 10,000 PNU/ml 1.25 2.5 5 Fusarium Mllinifrme 20,000 PNU/ml 2,500 PNU/mL 5,000 PNU/ml 10,000 PNU/ml 1.25 2.5 5 Insects d HTD Can mix dust mite and mlds. Cannt mix pllens with mlds Hney Bee Venm 100 μg/ml 100 μg/ml a Individual antigen cncentratin in mix is 1/5 f ttal PNUs Yellw Jacket Venm 100 μg/ml 100 μg/ml b Individual antigen cncentratin in mix is 1/6 f ttal PNUs Yellw Hrnet Venm 100 μg/ml 100 μg/ml c Kentucky Blue/June, Meadw Fescue, Orchard, Perennial Rye, Redtp, Wasp Venm 100 μg/ml 100 μg/ml Sweet vernal, Timthy Mixed Vespid Venm 300 μg/ml 300 μg/ml d Insects are n a REGULAR schedule (1 ml/injectin) ON TARGET

Methds New dsing guides were used ver the curse f 4 mnths with ccasinal minr mdificatins Unknwn whether the rdering prvider used the new dsing guide Educatin was prvided in the frm f 1:1 caching, didactic training sessins and real time guidance At the end f 4 mnths the 10 mst recent IT prescriptins were evaluated 58 allergen data pints Results cmpared t thse btained prir t initiatin f the new guide

Lw 9% All Antigens Pre Implementatin Apprpriate 25% Very lw 35% High 13% N/A 9% Very high 9% All Antigens Pst Implementatin Relative imprvement = 128% Abslute imprvement = 32% Apprpriate 57% High 10% Lw 7% Very lw 7% N/A 16% Very high 3% N = 58

All Antigens Excluding Mlds (Pre) Lw 10% Very lw 38% Apprpriate 28% High 14% Very high 10% All Antigens Excluding Mlds (Pst) Relative imprvement = 143% Abslute imprvement = 40% p = < 0.0001 Apprpriate 68% Lw 8% Very lw 8% 4% High 12% N = 49

Standardized Antigens (Pre) Apprpriate 46% High 25% Very Lw 8% Very high 21% Standardized Antigens (Pst) n Relative imprvement = 74% Abslute imprvement = 34% p = < 0.0001 Apprpriate 80% High 20% N = 20

Cnclusins Implementatin f the new dsing guide significantly imprves the accuracy f dsing IT Using antigen mixes fr SCIT rarely prvides sufficient amunts f each individual antigen t dse within practice parameter guidelines Mst antigens can reach a sufficient dse using a 0.5 ml/sht schedule alne

Future Directins Lk at sht reactin rates befre and after implementatin f the dsing guide Review charts frm thse with previus sht reactins t see if verdsed

Special Thanks Sameer Mathur, MD, PhD 1 Sujani Kakumanu, MD 1 Diane Dierdrff, CPhT 2 University f Wiscnsin Hspitals and Clinics Divisin f allergy and Immunlgy 1 Pharmacy 2